Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer

Wilkinson-Ryan, Ivy; Binder, Pratibha; Pourabolghasem, Shabnam; Al-Hammadi, Noor; Fuh, Katherine C.; Hagemann, Andrea R.; Thaker, Premal H.; Schwarz, Julie K.; Mutch, David G.; Powell, Matthew A.

doi:10.1016/j.ygyno.2014.05.002

Cited by 19 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon activation of HER RTKs, the phosphorylated tyrosines in the carboxyl-terminal regulatory tail of HER3 can form six docking sites for recruitment of the p85 adaptor subunit of phosphatidylinositol 3-kinase (PI3K) ( 71 ). Subsequently, the p110 catalytic subunit of PI3K phosphorylates phosphatidylinositol-4,5-biphosphate (PIP2) to generate phosphatidylinositol ( 3 , 4 , 5 )-triphosphate (PIP3), which then leads to the membrane recruitment and activation of proteins that contain a phospholipid-binding (PH) domain, such as phosphoinositide-dependent kinase (PDK) 1 ( 72 ). The activated PDK1 phosphorylates AKT-Thr308 and leads to the initial AKT activation ( 72 ).…”

Section: Akt Signaling Pathwaymentioning

confidence: 99%

“…As a staple approach for cancer treatment, radiation therapy plays a critical role in local disease control. When combined with chemotherapy (i.e., chemoradiation), radiation provides additional benefits, which give better disease control and significantly improve cancer patient survival ( 1 – 3 ). However, radioresistance and the presence of residual disease after radiation therapy remain major problems that result in the loss of the therapy effectiveness ( 4 – 7 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiation-induced signaling pathways that promote cancer cell survival (Review)

Hein

Ouellette

Yan

2014

International Journal of Oncology

160

122

View full text Add to dashboard Cite

Radiation therapy is a staple cancer treatment approach that has significantly improved local disease control and the overall survival of cancer patients. However, its efficacy is still limited by the development of radiation resistance and the presence of residual disease after therapy that leads to cancer recurrence. Radiation impedes cancer cell growth by inducing cytotoxicity, mainly caused by DNA damage. However, radiation can also simultaneously induce multiple pro-survival signaling pathways, such as those mediated by AKT, ERK and ATM/ATR, which can lead to suppression of apoptosis, induction of cell cycle arrest and/or initiation of DNA repair. These signaling pathways act conjointly to reduce the magnitude of radiation-induced cytotoxicity and promote the development of radioresistance in cancer cells. Thus, targeting these pro-survival pathways has great potential for the radiosensitization of cancer cells. In the present review, we summarize the current literature on how these radiation-activated signaling pathways promote cancer cell survival.

show abstract

Section: Akt Signaling Pathwaymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Radiation-induced signaling pathways that promote cancer cell survival (Review)

Hein

Ouellette

Yan

2014

International Journal of Oncology

160

122

View full text Add to dashboard Cite

show abstract

“…With inconsistent results of CT, some suggested that combination therapy and/or multimodality strategy might be another choice. 7 , 13 – 15 However, there is no agreement about the sequence of CT or RT, as well as the regimen of CT. 8 , 10 , 18 , 21 , 22 To investigate the outcome of the patients with advanced-stage E-EC and clarify the role of postoperative adjuvant therapy for these patients, the Taiwanese Gynecologic Oncology Group (TGOG) conducted this study.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer

Chen

Chang

et al. 2016

Medicine

View full text Add to dashboard Cite

In the management of patients with advanced-stage pure endometrioid-type endometrial cancer (E-EC), such as positive lymph nodes (stage III) or stage IV, treatment options are severely limited. This article aims to investigate the outcome of women with FIGO III-IV E-EC (based on FIGO 2009 system).The retrospective cohort study, based on the Taiwanese Gynecologic Oncology Group (TGOG-2005), enrolled patients undergoing staging surgery to have a pathologically confirmed FIGO III-IV E-EC from 22-member hospitals between 1991 and 2010.This cohort included 541 patients (stage III, n = 464; stage IV, n = 77). Five-year overall survival (OS) was 70.4%. Median progression-free survival (PFS) was 43 months (range 0–258 months) and median OS was 52 months (range 1–258 months). Multivariate analysis showed that FIGO stage, >1/2 myometrial invasion (hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.12–2.09; P = 0.007), histological grade 3 (HR 2.0, 95% CI 1.47–2.75; P < 0.001), and metastases of pelvic and para-aortic lymph nodes (PLN and PALN) (HR 2.75, 95% CI 1.13–6.72; P < 0.001) were independent risk factors for PFS. FIGO stage, >1/2 myometrial invasion (HR 1.89, 95% CI 1.34–2.64; P < 0.001), and histological grade 3 (HR 2.42, 95% CI 1.75–3.35; P < 0.001) influenced OS. Complete dissection of PLN and PALN (HR 0.27, 95% CI 0.16–0.45; P < 0.001, and HR 0.14, 95% CI 0.08–0.26; P < 0.001) and the following paclitaxel-based therapy (HR 0.61, 95% CI 0.79–0.92; P = 0.017, and HR 0.48; 95% CI 0.31–0.75; P = 0.001) provided the better PFS and OS, respectively.In management of women with FIGO III-V E-EC, combination of complete staging surgery (complete dissection of PLN and PALN is included) and the following paclitaxel-based therapy could provide the better chance to survive. Patients with tumor >1/2 myometrial invasion and histological grade 3 are risky for disease-related mortality.

show abstract

“…ND: not described. Data were obtained from different sources: uterine cervix 19,33 bladder 34 , anal/rectal 35,36 , prostate 37,38 , and endometrial 39 .…”

Section: Introductionmentioning

confidence: 99%

Epidemiological Profile, Gastrointestinal Toxicity, and Treatment of Pelvic Cancers in Patients Managed with Radiotherapy to the Abdominal Pelvic Area

Cetina¹,

Serrano-Olvera

Flores-Cisneros

et al. 2018

RIC

View full text Add to dashboard Cite

Mexico has seen an increase in cancer prevalence in its entire population as well as particular age ranges, predominantly the older segment. The most frequently reported pelvic cancers in Mexico are cervical, endometrial, bladder, prostate, rectum, and anal canal. Approximately 80% of the population diagnosed with pelvic cancers present with locally advanced tumors and require concomitant chemoradiotherapy, sequential chemoradiotherapy, or radiotherapy alone. The toxicity of any of these treatment modalities may be manifested as intestinal injury, a significant problem that can compromise the response to treatment, the patient's nutritional state, quality of life, and survival. In this article, we will approach key aspects in nutrition as well as the epidemiological characteristics and toxicities in patients affected by these pelvic tumors.

show abstract

Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer

Cited by 19 publications

References 25 publications

Radiation-induced signaling pathways that promote cancer cell survival (Review)

Radiation-induced signaling pathways that promote cancer cell survival (Review)

Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer

Epidemiological Profile, Gastrointestinal Toxicity, and Treatment of Pelvic Cancers in Patients Managed with Radiotherapy to the Abdominal Pelvic Area

Contact Info

Product

Resources

About